JPWO2020161214A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020161214A5 JPWO2020161214A5 JP2021546257A JP2021546257A JPWO2020161214A5 JP WO2020161214 A5 JPWO2020161214 A5 JP WO2020161214A5 JP 2021546257 A JP2021546257 A JP 2021546257A JP 2021546257 A JP2021546257 A JP 2021546257A JP WO2020161214 A5 JPWO2020161214 A5 JP WO2020161214A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802511P | 2019-02-07 | 2019-02-07 | |
| US62/802,511 | 2019-02-07 | ||
| EP19305173.7A EP3693023A1 (en) | 2019-02-11 | 2019-02-11 | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| EP19305173.7 | 2019-02-11 | ||
| EP19305504.3 | 2019-04-18 | ||
| EP19305504 | 2019-04-18 | ||
| PCT/EP2020/052932 WO2020161214A1 (en) | 2019-02-07 | 2020-02-06 | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523155A JP2022523155A (ja) | 2022-04-21 |
| JP2022523155A5 JP2022523155A5 (https=) | 2023-01-26 |
| JPWO2020161214A5 true JPWO2020161214A5 (https=) | 2023-01-26 |
| JP7597718B2 JP7597718B2 (ja) | 2024-12-10 |
Family
ID=71947024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546257A Active JP7597718B2 (ja) | 2019-02-07 | 2020-02-06 | 肺がんを処置するための抗ｃｅａｃａｍ５イムノコンジュゲートの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220080053A1 (https=) |
| EP (1) | EP3920972A1 (https=) |
| JP (1) | JP7597718B2 (https=) |
| KR (1) | KR20210124260A (https=) |
| CN (1) | CN114173823A (https=) |
| AU (1) | AU2020219405A1 (https=) |
| BR (1) | BR112021014636A2 (https=) |
| CA (1) | CA3129106A1 (https=) |
| CO (1) | CO2021010032A2 (https=) |
| IL (1) | IL285306A (https=) |
| MX (1) | MX2021009514A (https=) |
| SG (1) | SG11202107843WA (https=) |
| TW (1) | TW202045539A (https=) |
| WO (1) | WO2020161214A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2021214222A1 (en) * | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
| US12564642B2 (en) | 2020-11-10 | 2026-03-03 | Sanofi | CEACAM5 antibody-drug conjugate formulation |
| WO2023099682A1 (en) | 2021-12-02 | 2023-06-08 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
| EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| AU2024286132A1 (en) | 2023-06-05 | 2026-01-22 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies |
| WO2025169012A1 (en) | 2024-02-06 | 2025-08-14 | Sanofi | Methods of treating ceacam5-expressing cancers |
| TW202600608A (zh) * | 2024-02-27 | 2026-01-01 | 美商必治妥美雅史谷比公司 | 抗ｃｅａｃａｍ５抗體及其用途 |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| NZ613647A (en) * | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| HUE033369T2 (en) * | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| WO2023099682A1 (en) * | 2021-12-02 | 2023-06-08 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
| KR20250154496A (ko) * | 2023-03-01 | 2025-10-28 | 사노피 | Ceacam5를 발현하는 신경내분비암을 치료하기 위한 항-ceacam5 면역접합체의 용도 |
-
2020
- 2020-02-06 WO PCT/EP2020/052932 patent/WO2020161214A1/en not_active Ceased
- 2020-02-06 SG SG11202107843WA patent/SG11202107843WA/en unknown
- 2020-02-06 BR BR112021014636A patent/BR112021014636A2/pt unknown
- 2020-02-06 MX MX2021009514A patent/MX2021009514A/es unknown
- 2020-02-06 KR KR1020217025390A patent/KR20210124260A/ko not_active Ceased
- 2020-02-06 US US17/425,603 patent/US20220080053A1/en active Pending
- 2020-02-06 EP EP20702487.8A patent/EP3920972A1/en active Pending
- 2020-02-06 JP JP2021546257A patent/JP7597718B2/ja active Active
- 2020-02-06 CA CA3129106A patent/CA3129106A1/en active Pending
- 2020-02-06 AU AU2020219405A patent/AU2020219405A1/en active Pending
- 2020-02-06 CN CN202080012901.6A patent/CN114173823A/zh active Pending
- 2020-02-07 TW TW109103884A patent/TW202045539A/zh unknown
-
2021
- 2021-07-29 CO CONC2021/0010032A patent/CO2021010032A2/es unknown
- 2021-08-02 IL IL285306A patent/IL285306A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals | |
| JP7512361B2 (ja) | Ｒｏｒ１抗体免疫複合体 | |
| Marei et al. | Potential of antibody–drug conjugates (ADCs) for cancer therapy | |
| Yaghoubi et al. | Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy | |
| Nasiri et al. | Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy | |
| Goldenberg et al. | Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan | |
| Birrer et al. | Antibody-drug conjugate-based therapeutics: state of the science | |
| Trail et al. | Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design | |
| Chari et al. | Antibody–drug conjugates: an emerging concept in cancer therapy | |
| JP2020525542A5 (https=) | ||
| JP7512202B2 (ja) | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 | |
| Mack et al. | The next generation of antibody drug conjugates | |
| AU2025226765A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| Zhou et al. | Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice | |
| JP2016512832A5 (https=) | ||
| Jackson et al. | Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates: Jackson and Stover | |
| JP2014533954A5 (https=) | ||
| JP2022513684A (ja) | 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法 | |
| TW202207990A (zh) | 含有α-烯醇酶抗體之藥物共軛物及其用途 | |
| JPWO2020161214A5 (https=) | ||
| D’Angelo et al. | An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| KR20250154496A (ko) | Ceacam5를 발현하는 신경내분비암을 치료하기 위한 항-ceacam5 면역접합체의 용도 | |
| CN117304316A (zh) | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 | |
| Aesoy et al. | Cyanobacterial anticancer compounds in clinical use: Lessons from the dolastatins and cryptophycins |